Novel 2,5-dideoxystreptamine derivatives targeting the ribosomal decoding site RNA

Dionisios Vourloumis; Masayuki Takahashi; Geoffrey C Winters; Klaus B Simonsen; Benjamin K Ayida; Sofia Barluenga; Seema Qamar; Sarah Shandrick; Qiang Zhao; Thomas Hermann

doi:10.1016/s0960-894x(02)00759-x

Novel 2,5-dideoxystreptamine derivatives targeting the ribosomal decoding site RNA

Bioorg Med Chem Lett. 2002 Dec 2;12(23):3367-72. doi: 10.1016/s0960-894x(02)00759-x.

Authors

Dionisios Vourloumis¹, Masayuki Takahashi, Geoffrey C Winters, Klaus B Simonsen, Benjamin K Ayida, Sofia Barluenga, Seema Qamar, Sarah Shandrick, Qiang Zhao, Thomas Hermann

Affiliation

¹ Department of Medicinal Chemistry, Anadys Pharmaceuticals, Inc., San Diego, CA 92121, USA. dvourloumis@anadyspharma.com

PMID: 12419363
DOI: 10.1016/s0960-894x(02)00759-x

Abstract

The ribosomal decoding site is the target of aminoglycoside antibiotics that specifically recognize an internal loop RNA structure. We synthesized RNA-targeted 2,5-dideoxystreptamine-4-amides in which a sugar moiety in natural aminoglycosides is replaced by heterocycles.

Publication types

Research Support, U.S. Gov't, P.H.S.

MeSH terms

Aminoglycosides
Anti-Bacterial Agents / chemistry*
Anti-Bacterial Agents / pharmacology*
Binding Sites
Hexosamines / chemistry*
Hexosamines / pharmacology*
Luciferases / genetics
Models, Molecular
Protein Biosynthesis / drug effects
RNA, Ribosomal / drug effects
RNA, Ribosomal / metabolism*
Structure-Activity Relationship
Transcription, Genetic / drug effects

Substances

Aminoglycosides
Anti-Bacterial Agents
Hexosamines
RNA, Ribosomal
Luciferases